martes, 27 de enero de 2015

Benzodiazepine Often Used in Older People Despite Risks - NIH Research Matters - National Institutes of Health (NIH)

Benzodiazepine Often Used in Older People Despite Risks - NIH Research Matters - National Institutes of Health (NIH)

National Institutes of Health (NIH) - Turning Discovery Into Health

Contact Us

Mailing Address:
NIH Research Matters
Bldg. 31, Rm. 5B64A, MSC 2094
Bethesda, MD 20892-2094

About NIH Research Matters

Editor: Harrison Wein, Ph.D.
Assistant Editors: Vicki Contie, Carol Torgan, Ph.D.
NIH Research Matters is a weekly update of NIH research highlights from the Office of Communications and Public Liaison, Office of the Director, National Institutes of Health.
ISSN 2375-9593


Benzodiazepine Often Used in Older People Despite Risks

At a Glance

  • Despite known risks for older people, use of benzodiazepines—a class of sedative and anti-anxiety medications—remains common in this group.
  • The findings raise questions about why so many prescriptions are written for older adults when there are often safer alternatives.
Benzodiazepines include the medications alprazolam (Xanax), diazepam (Valium), and lorazepam (Ativan). These drugs are widely prescribed to treat anxiety and sleep problems. But while effective, they have serious risks—especially when used over long periods. Long-term use can lead to dependence and withdrawal symptoms when discontinued. Benzodiazepines can impair cognition, mobility, and driving skills in older people, as well as increase the risk of falls. A recent study also found an association between benzodiazepine use in older people and increased risk of Alzheimer’s disease.
Older man talking to doctor.
The analysis reveals worrisome patterns in the prescribing of benzodiazepines for older adults.
Practice guidelines now recommend psychotherapy approaches and antidepressants as the initial treatment for anxiety. For insomnia, guidelines recommend behavioral interventions as first treatment.
Despite the large number of benzodiazepine prescriptions in the United States — 85 million in 2007 — relatively little has been known about prescription patterns. Dr. Mark Olfson at the New York State Psychiatric Institute and Columbia University, Dr. Marissa King at Yale University, and Dr. Michael Schoenbaum at NIH’s National Institute of Mental Health (NIMH) thus examined rates of benzodiazepine use by sex and age.
The researchers examined prescription patterns from 2008 using data from a national prescription database (IMS LifeLink LRx Longitudinal Prescription database) and a national database on medical expenditures collected by the Agency for Healthcare Research and Quality. The study appeared online on December 17, 2014, in JAMA Psychiatry.
Among all adults ages 18 to 80 years, about 1 in 20 received a benzodiazepine prescription in 2008. This fraction rose substantially with age, from 2.6% among those 18 to 35, to 8.7% in those 65 to 80. Long-term use—for more than 120 days—also increased markedly with age. Of people 65 to 80 who used benzodiazepines, 31.4% received prescriptions for long-term use, vs. 14.7% of adults 18 to 35.
In all age groups, women were about twice as likely as men to receive benzodiazepines. Among women 65 to 80 years old, 1 in 10 was prescribed one of these medications, with almost a third of those receiving long-term prescriptions.
Most prescriptions for benzodiazepines were written by non-psychiatrists. Overall, about two-thirds of prescriptions for long-term use were written by non-psychiatrists; for adults 65 to 80, the figure was 9 out of 10.
“These medications can pose real risks, and there are often safer alternatives available,” Schoenbaum says. “Our findings strongly suggest that we need strategies to reduce benzodiazepine use, particularly for older women.”

RELATED LINKS:

Reference: Benzodiazepine Use in the United States. Olfson M, King M, Schoenbaum M. JAMA Psychiatry. 2014 Dec 17. doi: 10.1001/jamapsychiatry.2014.1763. [Epub ahead of print]. PMID: 25517224.
Funding: NIH’s National Institute of Mental Health (NIMH); the Agency for Healthcare Research and Quality; and the New York State Psychiatric Institute.

No hay comentarios:

Publicar un comentario